Cohort Study: Use of 5α-reductase Inhibitors is Associated with Delayed Prostate Cancer Diagnosis and Increased Mortality in Men Undergoing PSA Screening

Association of Treatment With 5α-Reductase Inhibitors With Time to Diagnosis and Mortality in Prostate Cancer – JAMA Internal Medicine (free for a limited period)

Commentary: 5-ARIs Tied to Delayed Prostate Cancer Dx, Worse Outcomes – MedPage Today (free registration required)

Related Commentary on Twitter

Prediagnostic use of 5α-reductase inhibitors is associated with delayed #prostatecancer diagnosis and increased mortality in men who underwent prostate-specific antigen screening https://t.co/ccRkKrExob

— JAMA Internal Medicine (@JAMAInternalMed) May 7, 2019